Carin A Uyl-de Groot

Carin A Uyl-de Groot

UNVERIFIED PROFILE

Are you Carin A Uyl-de Groot?   Register this Author

Register author
Carin A Uyl-de Groot

Carin A Uyl-de Groot

Publications by authors named "Carin A Uyl-de Groot"

Are you Carin A Uyl-de Groot?   Register this Author

97Publications

1328Reads

13Profile Views

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.

Eur J Health Econ 2019 Sep 20. Epub 2019 Sep 20.

Erasmus School of Health Policy & Management/Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. box 1738, 3000 DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10198-019-01117-3DOI Listing
September 2019

Systematic reviews as a "lens of evidence": Determinants of cost-effectiveness of breast cancer screening.

Cancer Med 2019 Sep 30. Epub 2019 Sep 30.

The section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2498DOI Listing
September 2019

Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma.

Eur J Surg Oncol 2019 05 5;45(5):825-831. Epub 2019 Feb 5.

Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2019.01.225DOI Listing
May 2019

Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non-Small Cell Lung Cancer Using Real-World Data.

Value Health 2019 Mar 26;22(3):322-331. Epub 2018 Oct 26.

Center for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2018.08.007DOI Listing
March 2019

[Loss is gain? Discarding TNF-α inhibitors].

Ned Tijdschr Geneeskd 2019 Mar 21;163. Epub 2019 Mar 21.

Erasmus Universiteit, Institute for Medical Technology Assessment, Rotterdam.

View Article

Download full-text PDF

Source
March 2019

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis.

Onco Targets Ther 2019 20;12:1413-1421. Epub 2019 Feb 20.

Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S189438DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388947PMC
February 2019

A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia.

Pediatr Blood Cancer 2019 01 23;66(1):e27458. Epub 2018 Sep 23.

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27458DOI Listing
January 2019

Reply to 'Economic comments on proposal for a novel cancer drug pricing model'.

Nat Rev Clin Oncol 2018 09;15(9):588

Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0084-1DOI Listing
September 2018

Reply to 'Response to proposal for a novel cancer drug pricing model'.

Nat Rev Clin Oncol 2018 08;15(8):528-529

Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0063-6DOI Listing
August 2018

Sustainability and affordability of cancer drugs: a novel pricing model.

Nat Rev Clin Oncol 2018 07;15(7):405-406

Department of Haematology, Erasmus University Medical Center, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0027-xDOI Listing
July 2018

Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.

Pharmacoeconomics 2018 04;36(4):505

Institute for Medical Technology Assessment, Institute of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-018-0634-5DOI Listing
April 2018

Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'.

Pharmacoeconomics 2018 03;36(3):381-382

Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-018-0620-yDOI Listing
March 2018

Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe.

Pharmacogenomics 2018 02 15;19(3):213-226. Epub 2018 Jan 15.

Erasmus School of Health Policy & Management, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2017-0140DOI Listing
February 2018

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.

Pharmacoeconomics 2018 01;36(1):91-103

Institute for Medical Technology Assessment, Institute of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-017-0557-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775392PMC
January 2018

A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.

Pediatr Blood Cancer 2017 Dec 2;64(12). Epub 2017 Aug 2.

Pediatric Oncology and Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.26651DOI Listing
December 2017

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.

PLoS One 2017 16;12(8):e0182613. Epub 2017 Aug 16.

Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182613PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559086PMC
October 2017

Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the Netherlands.

Clin Lung Cancer 2017 09 30;18(5):e341-e347. Epub 2015 Nov 30.

Institute for Medical Technology Assessment, Erasmus University, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2015.11.011DOI Listing
September 2017

Reply to X. Armoiry et al.

J Clin Oncol 2017 09 12;35(25):2976-2977. Epub 2017 Jul 12.

Chrissy H.Y. van Beurden-Tan, Erasmus MC Cancer Institute, Rotterdam, Netherlands; Margreet G. Franken, Erasmus University Rotterdam, Rotterdam, Netherlands; Hedwig M. Blommestein, Erasmus University Rotterdam, Rotterdam, Netherlands; Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam, Netherlands; Hedwig M. Blommestein, Comprehensive Cancer Organisation, Utrecht, Netherlands; Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, Netherlands; and Pieter Sonneveld, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.7569DOI Listing
September 2017

Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.

Value Health 2016 Sep - Oct;19(6):834-843. Epub 2016 Aug 26.

Institute for Medical Technology Assessment/Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2016.05.008DOI Listing
May 2017

Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.

J Clin Oncol 2017 Apr 27;35(12):1312-1319. Epub 2017 Feb 27.

Chrissy H.Y. van Beurden-Tan and Pieter Sonneveld, Erasmus MC Cancer Institute; Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.1663DOI Listing
April 2017

Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences.

Value Health 2017 04 6;20(4):627-636. Epub 2016 Apr 6.

Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2016.02.007DOI Listing
April 2017

MODEL-BASED COST-EFFECTIVENESS OF CONVENTIONAL AND INNOVATIVE CHEMO-RADIATION IN LUNG CANCER.

Int J Technol Assess Health Care 2017 Jan 10;33(6):681-690. Epub 2017 Nov 10.

Department of Epidemiology and Biostatistics,VU University Medical

View Article

Download full-text PDF

Source
https://www.cambridge.org/core/product/identifier/S026646231
Publisher Site
http://dx.doi.org/10.1017/S0266462317000939DOI Listing
January 2017

Using Appropriate Methods in Cost-Effectiveness Analyses: The Case of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease.

Biol Blood Marrow Transplant 2016 11 13;22(11):2109-2110. Epub 2016 Sep 13.

Institute of Health Policy and Management/Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.08.022DOI Listing
November 2016

Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.

Leuk Res 2016 11 3;50:37-45. Epub 2016 Sep 3.

Institute for Medical Technology Assessment, Institute of Health Policy and Management, Erasmus University Rotterdam, The Netherlands; Netherlands Comprehensive Cancer Organisation, Netherlands Cancer Registry Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.09.005DOI Listing
November 2016

Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.

Urology 2016 Sep 11;95:121-7. Epub 2016 May 11.

Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2016.04.042DOI Listing
September 2016

A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.

Eur J Haematol 2016 Feb 7;96(2):198-208. Epub 2015 May 7.

Department of Health Policy & Management/institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12571DOI Listing
February 2016

Cost-utility of sentinel lymph node biopsy in cT1-T2N0 oral cancer.

Oral Oncol 2016 Feb 26;53:20-6. Epub 2015 Nov 26.

Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2015.11.011DOI Listing
February 2016

THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS.

Int J Technol Assess Health Care 2016 Jan 22;32(1-2):46-53. Epub 2016 Mar 22.

Institute of Health Policy and Management,Erasmus University Rotterdam;Institute for Medical Technology Assessment,Erasmus University Rotterdam.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S0266462316000064DOI Listing
January 2016

Primary care in cancer control: towards mature cancer care.

Lancet Oncol 2015 Sep;16(12):1226-7

Erasmus MC, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00294-6DOI Listing
September 2015

A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.

Pharmacoeconomics 2015 Jun;33(6):551-60

Department of Health Policy and Management, institute for Medical Technology Assessment, Erasmus University, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs40273-015-02
Web Search
http://link.springer.com/10.1007/s40273-015-0260-4
Publisher Site
http://dx.doi.org/10.1007/s40273-015-0260-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445765PMC
June 2015

Individualized positron emission tomography-based isotoxic accelerated radiation therapy is cost-effective compared with conventional radiation therapy: a model-based evaluation.

Int J Radiat Oncol Biol Phys 2015 Mar;91(4):857-65

Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2014.12.012DOI Listing
March 2015

Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement.

Health Policy 2015 Feb 22;119(2):186-94. Epub 2014 Nov 22.

Department of Haematology, Erasmus University Medical Centre, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healthpol.2014.11.010DOI Listing
February 2015

Evaluation of patient registries supporting reimbursement decisions: the case of oxaliplatin for treatment of stage III colon cancer.

Value Health 2015 Jan;18(1):84-90

Department of Epidemiology, Unit Health Technology Assessment, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2014.10.008DOI Listing
January 2015

Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.

Eur J Haematol 2014 2;92(5):398-406. Epub 2014 Mar 2.

Department of Health Policy & Management, Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12264DOI Listing
December 2014

Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study.

Eur J Haematol 2014 Sep 18;93(3):198-206. Epub 2014 Apr 18.

Institute for Medical Technology Assessment/Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12324DOI Listing
September 2014

The Drug Reimbursement Decision-Making System in Iran.

Value Health Reg Issues 2014 May 24;3:174-181. Epub 2014 May 24.

Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vhri.2014.04.010DOI Listing
May 2014

Cost-effectiveness and clinical implications of advanced bearings in total knee arthroplasty: a long-term modeling analysis.

Int J Technol Assess Health Care 2014 Apr 28;30(2):218-25. Epub 2014 Apr 28.

Institute for Medical Technology Assessment,Erasmus University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S0266462314000129DOI Listing
April 2014

Real-world cost-effectiveness of oxaliplatin in stage III colon cancer: a synthesis of clinical trial and daily practice evidence.

Pharmacoeconomics 2013 Aug;31(8):703-18

Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University, Burgemeester Oudlaan 50, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-013-0061-6DOI Listing
August 2013

Efficient allocation of novel agents in multiple myeloma: a work in progress.

Oncologist 2013 8;18(1):5-7. Epub 2013 Jan 8.

Institute for Medical Technology Assessment, Erasmus University, P.O. Box 1738, S000DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2012-0484DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556256PMC
July 2013

The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia.

Pharmacoeconomics 2013 Jul;31(7):605-21

Institute for Medical Technology Assessment/Institute of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-013-0058-1DOI Listing
July 2013

The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands.

Leuk Res 2013 Mar 12;37(3):245-50. Epub 2012 Oct 12.

Institute for Medical Technology Assessment/Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.09.018DOI Listing
March 2013

Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands.

Eur J Cancer 2013 Jan 16;49(1):8-16. Epub 2012 Jul 16.

Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S095980491200501
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2012.06.010DOI Listing
January 2013

Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.

Med Decis Making 2012 Jul-Aug;32(4):554-68. Epub 2011 Nov 22.

Erasmus University of Rotterdam, Rotterdam, the Netherlands (MMV, AL, CAU, EAS)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0272989X11427761DOI Listing
November 2012

Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.

Expert Rev Anticancer Ther 2012 Jun;12(6):839-54

Institute for Medical Technology Assessment/Institute of Health Policy & Management, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/era.12.42
Publisher Site
http://dx.doi.org/10.1586/era.12.42DOI Listing
June 2012

Condition-specific preference-based measures: benefit or burden?

Value Health 2012 May 9;15(3):504-13. Epub 2012 Feb 9.

iMTA/iBMG, Institute of Health Policy and Management/Institute for Medical Technology Assessment, Erasmus University of Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2011.12.003DOI Listing
May 2012

Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands.

Acta Oncol 2012 Jan 28;51(1):57-64. Epub 2011 Nov 28.

Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/0284186X.2011.633930DOI Listing
January 2012

Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.

Pharmacoeconomics 2012 Jan;30(1):17-34

Department of Epidemiology and Biostatistics, VU Medical Centre, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/11595000-000000000-00000DOI Listing
January 2012

Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: the influence of new medication and diagnostic technology.

Pediatr Blood Cancer 2011 Dec 25;57(6):1005-10. Epub 2011 May 25.

Department of Pediatrics, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.23197DOI Listing
December 2011

Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology.

Eur J Cancer 2011 Jul 9;47(10):1458-67. Epub 2011 May 9.

Institute for Medical Technology Assessment/Institute of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2011.04.005DOI Listing
July 2011

Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia.

Pharmacogenomics 2011 Mar;12(3):411-21

Institute for Medical Technology Assessment/Institute of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.10.187DOI Listing
March 2011

The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology.

Value Health 2010 Sep-Oct;13(6):712-9. Epub 2010 Jun 7.

Erasmus Universiteit Rotterdam, Institute for Medical Technology Assessment, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1524-4733.2010.00740.xDOI Listing
January 2011

Incorporating equity-efficiency interactions in cost-effectiveness analysis-three approaches applied to breast cancer control.

Value Health 2010 Aug 31;13(5):573-9. Epub 2010 Mar 31.

Institutes of Health Policy & Management and of Medical Technology Assessment, Erasmus Medical Centre, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1524-4733.2010.00718.xDOI Listing
August 2010

The economics of improved cancer survival rates: better outcomes, higher costs.

Expert Rev Pharmacoecon Outcomes Res 2010 Jun;10(3):283-92

Institute for Medical Technology Assessment, Institute of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/erp.10.27DOI Listing
June 2010

Chest CT and whole-body 18F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients.

J Nucl Med 2010 Feb;51(2):176-82

Institute for Medical Technology Assessment, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.109.067371DOI Listing
February 2010

Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.

Expert Rev Pharmacoecon Outcomes Res 2009 Jun;9(3):235-41

Institute for Medical Technology Assessment/Department of Health Policy and Management, Erasmus University Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/erp.09.15DOI Listing
June 2009

Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery.

Brachytherapy 2008 Oct-Dec;7(4):343-50. Epub 2008 Sep 10.

Department of Radiation-Oncology, Erasmus Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2008.05.001DOI Listing
January 2009

A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurrent laryngeal carcinoma after radiotherapy.

Contemp Clin Trials 2007 Nov 21;28(6):705-12. Epub 2007 Mar 21.

Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cct.2007.03.009DOI Listing
November 2007

The use of disease-specific outcome measures in cost-utility analysis: the development of Dutch societal preference weights for the FACT-L scale.

Pharmacoeconomics 2007 ;25(7):591-603

Institute for Medical Technology Assessment, Erasmus University Medical Center, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00019053-200725070-00005DOI Listing
October 2007

Inequalities in oncology care: Economic consequences of high cost drugs.

Eur J Cancer 2006 Nov 18;42(17):2887-92. Epub 2006 Sep 18.

Institute for Health Policy and Management, Erasmus MC Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2006.07.009DOI Listing
November 2006

Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care.

Eur J Cancer 2006 Nov 27;42(17):2862-6. Epub 2006 Sep 27.

Institute for Medical Technology Assessment, Erasmus MC, University Medical Centre, PO Box 1700, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2006.08.008DOI Listing
November 2006

Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas.

Eur Arch Otorhinolaryngol 2006 Aug 14;263(8):729-37. Epub 2006 May 14.

Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus MC, University Medical Centre Rotterdam, PO Box 1738, 3000 DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00405-006-0062-6DOI Listing
August 2006

Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia.

Breast J 2006 Jan-Feb;12 Suppl 1:S81-90

Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1075-122X.2006.00206.xDOI Listing
April 2006

Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.

Haematologica 2005 Oct;90(10):1422-32

Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
October 2005

Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?

Curr Opin Oncol 2005 Jul;17(4):392-6

Institute for Medical Technology Assessment, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.cco.0000168535.25330.6aDOI Listing
July 2005

Cost determinants in aggressive non-Hodgkin's lymphoma.

Haematologica 2005 May;90(5):661-71

Institute for Medical Technology Assessment, Erasmus MC, University Medical Center Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
May 2005

Economic assessment in the management of non-Hodgkin's lymphoma.

Expert Opin Pharmacother 2004 Dec;5(12):2529-48

University Medical Centre Rotterdam, Erasmus MC, Institute for Medical Technology Assessment, PO Box 1738, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.5.12.2529DOI Listing
December 2004

Costs of multiple myeloma and associated skeletal-related events in The Netherlands.

Expert Rev Pharmacoecon Outcomes Res 2004 Oct;4(5):565-72

Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, Room L3-105, PO Box 1738, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737167.4.5.565DOI Listing
October 2004

Chemotherapy and high-dose-rate brachytherapy in the management of advanced cancers of the nasopharynx: clinical impact of high technology--is it worth the cost?

Brachytherapy 2002 ;1(1):11-20

Department of Radiation-Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
June 2004

Cost-effectiveness and quality of life of granulocyte-colony stimulating factor (filgrastim) after radical vulvectomy and bilateral inguino-femoral lymphadenectomy: results of a randomized clinical trial.

Eur J Obstet Gynecol Reprod Biol 2004 May;114(1):77-82

Department of Health Care Policy and Management, Institute for Medical Technology Assessment, Erasmus Medical Center, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2003.09.018DOI Listing
May 2004

A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma.

Hematol J 2003 ;4(6):399-409

Erasmus Medical Center, University Medical Center, Institute for Medical Technology Assessment, Department of Health Policy and Management, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.thj.6200323DOI Listing
February 2004

Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.

Eur J Nucl Med Mol Imaging 2003 Nov 29;30(11):1444-9. Epub 2003 May 29.

Institute for Medical Technology Assessment, Erasmus Medical Centre/Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-003-1199-9DOI Listing
November 2003